TNF and rheumatoid arthritis: We recruited 17 RA patients (14F:3M, mean age 50.4 + 14.4 years, range 26–68 years) with long-standing disease (mean disease duration 103 ± 104,4 months, range 24–360) who were designed to start a subcutaneous anti-TNF drug.